Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on therapies for allergic and immunologic diseases, has announced positive initial results from its ALPHA-SOLAR long-term open-label trial. The trial evaluates navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema $(HAE)$ patients. The results showed a 95% mean monthly attack-rate reduction in the Q3M arm and an 86% reduction in the Q6M arm, demonstrating the drug's favorable safety profile. These findings were presented at the European Academy of Allergy and Clinical Immunology Annual Congress on June 13, 2025. Astria has also initiated the pivotal Phase 3 ALPHA-ORBIT trial, which is currently enrolling patients to further evaluate navenibart's efficacy and safety.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.